CLRPF
PINK Clarity Pharmaceuticals Ltd.$1.50 ↓ -0.10 (-6.24%) Trading Down from the previous close of $1.60, $0.15 below the day’s high of $1.65
- YTD change
- -33.86%
- vs 20-day SMA
- -7.36%
- vs 200-day SMA
- -31.60%
Price ranges
Price & Performance
-0.70 (-31.82%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 76.6% away from all-time highs of $6.40
- CLRPF is down 34% since the beginning of the year
- CLRPF is down 55% over the past 12 months
- CLRPF is down 20% over the past 1 month
- 2% of all CLRPF investors are betting against CLRPF
CLRPF reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -55.5%.
- Previous minute
- +$0.00
- Last hour
- -$0.15
- Last 5 days
- +2.39%
- vs 8-day SMA
- -0.37%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. It engages in research and development and clinical stage evaluation of its portfolio of novel radiopharmaceuticals products. The company was founded by Matthew Harris on April 8, 2010 and is headquartered in Eveleigh, Australia.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.